Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy.

Autor: Mac Curtain BM; Hepatopancreatobiliary Group, St Vincent's University Hospital, Dublin 4, Ireland., O'Brien L; Hepatopancreatobiliary Group, St Vincent's University Hospital, Dublin 4, Ireland., El Sherif O; National Liver Transplant Unit, St Vincent's University Hospital, Dublin 4, Ireland., Mc Cormack A; National Liver Transplant Unit, St Vincent's University Hospital, Dublin 4, Ireland., Carolan E; Department of Hepatology, Beaumont Hospital, Dublin 9, Ireland., Ryan JD; Department of Hepatology, Beaumont Hospital, Dublin 9, Ireland., O'Shea D; Department of Endocrinology, St Vincent's University Hospital, Dublin 4, Ireland., Gallagher TK; Hepatopancreatobiliary Group, St Vincent's University Hospital, Dublin 4, Ireland.; National Liver Transplant Unit, St Vincent's University Hospital, Dublin 4, Ireland.
Jazyk: angličtina
Zdroj: Gastroenterology and hepatology from bed to bench [Gastroenterol Hepatol Bed Bench] 2024; Vol. 17 (1), pp. 17-27.
DOI: 10.22037/ghfbb.v17i1.2899
Abstrakt: Weight gain post-liver transplant can lead to adverse patient outcomes in the post-transplant period. Pharmacotherapy and other measures can be utilised to reduce the burden and occurrence of weight gain in this population. We explored the mechanism of action, safety, and efficacy of these medications, specifically GLP-1 receptor agonists and metformin, focusing on liver transplant patients. This scoping review was conducted in line with the scoping review structure as outlined by the PRISMA guidelines. Metformin and GLP-1 receptor agonists have been observed to be safe and effective in liver transplant patients. Experimental models have found liver-centric weight loss mechanisms in this drug cohort. There is a paucity of evidence about the use of antihyperglycemics in a post-transplant population for weight loss purposes. However, some small studies have shown strong safety and efficacy data. The evidence in relation to using these medications in patients with metabolic syndrome for weight loss warrants further study in a transplant population.
Competing Interests: There is no conflict of interest for authors of this article.
(© 2024, Gastroenterology and Hepatology From Bed to Bench (GHFBB).)
Databáze: MEDLINE
Externí odkaz: